
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Robert Hugin, Chairman of Celgene and PhRMA, talks about the challenges ahead for the industry organization
Robert Hugin, Chairman of Celgene and PhRMA, talks about the challenges ahead for the industry organization.






